Prognostic implications of cyclins (D1, E, A), cyclin-dependent kinases (CDK2, CDK4) and tumor-suppressor genes (pRb, p16(INK4A)) in childhood acute lymphoblastic leukemia

International Journal of Cancer

Volumn 74, Issue 5, 1997, Pages 508-512

  Volm, Manfred ^a   Koomägi, Reet ^a   Stammler, Gert ^a   Rittgen, Werner ^a   Zintl, Felix ^b   Sauerbrey, Axel ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; CYCLINE; PROTEIN P16; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER REGRESSION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADOLESCENT; CDC2-CDC28 KINASES; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; CYCLINS; FEMALE; GENES, P16; GENES, RETINOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 1842415951     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971021)74:5<508::AID-IJC5>3.0.CO;2-7     Document Type: Article

References (23)

1. BENNET, J.M., CATOVSKI, D., DANIEL, M.T., FLANDRIN, G., GALTON, D.A.G., GRALNICK, H.R. and SULTAN, C., French-American-British (FAB) cooperative group. Proposal for the classification of the acute leukemias. Brit. J. Haematol., 33, 451-458 (1976).
2. CHELLAPPAN, S.P., HIEBERT, S., MUDRY, J.M., HOROWITZ, J.M. and NEVINS, J.R., The E2F transcription factor is a cellular target for the Rb protein. Cell, 65, 1053-1062 (1991).
3. CHEN, P.L., SCULLY, P., SHEW, J.Y., WANG, J.Y. and LEE, W.H., Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell, 58, 1193-1208 (1989).
4. CORDON-CARDO, C., Mutation of cell-cycle regulators. Biological and clinical implications for human neoplasia. (Review). Amer. J. Pathol., 147, 545-560 (1995).
5. DUTTA, A., CHANDRA, R., LEITER, L.M. and LESTER, S., Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc. nat. Acad. Sci. (Wash.), 92, 5386-5390 (1995).
6. KAMB, A., GRUIS, N.A., WEAVER-FELDHAUS; J., LIN, Q., HARSHMAN, K., TAVTIGIAN, S.V., STOCKERT, E., DAY, R.R., JOHNSON, B.E. and SKOLNICK, M.H., A cell-cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440 (1994).
7. KEES, U.R., RANFORD, P.R. and HATZIS, M., Deletions of the p16 gene in pediatric leukemia and corresponding cell lines. Oncogene, 12, 2235-2239 (1996).
8. KEYOMARSI, K. and PARDEE, A.B., Redundant cyclin over-expression and gene amplification in breast-cancer cells. Proc. nat. Acad. Sci. (Wash.), 90, 1112-1116 (1993).
9. KORNBLAU, S.M., XU, H.J.X., ZHANG, W., HU, S.X., BERAN, M., SMITH, T.L., HESTER, J., ESTEY, E., BENEDICT, W.F. and DEISSEROTH, A.B., Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood, 84, 256-261 (1994).
10. MAELANDSMO, G.M., FLORENES, V.A., HOVIG, E., OYJORD, T., ENGEBRAATEN, O., HOLM, R., BORRESEN, A.-L. and FODSTAD, O., Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Brit. J. Cancer, 73, 909-916 (1996).
11. MICHALIDES, R., VAN VEELEN, N., HART, A., LOFTUS, B., WIENTJENS, E. and BALM, A., Over-expression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous-cell carcinomas of the head and neck. Cancer Res., 55, 975-978 (1995).
12. 1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell, 65, 381-393 (1991).
13. NAITOH, H., SHIBATA, J., KAWAGUCHI, A., KODAMA, M. and HATTORI, T., Over-expression and localization of cyclin-D1 mRNA and antigen in esophageal cancer. Amer. J. Pathol., 146, 1161-1169 (1995).
14. PATERLINI, P., FLEJOU, J.F., DEMITRI, M.S., PISI, E., FRANKO, D. and BRECHOT, C., Structure and expression of the cyclin-A gene in human primary liver cancer. Correlation with low cytometric parameters. J. Hepatol., 23, 47-52 (1995).
15. QUESNEL, B., PREUDHOMME, C., PHILIPPE, N., VANRUMBEKE, M., DERVITE, I., LAI, J.L., BAUTERS, F., WATTEL, E. and FENOUX, P., p16-gene homozygous deletions in acute lymphoblastic leukemia. Blood, 85, 657-663 (1995).
16. SAUERBREY, A., STAMMLER, G., ZINTL, F. and VOLM, M., Expression of prognostic value of the retinoblastoma tumor-suppressor gene Rb-1 in childhood acute lymphoblastic leukaemia. Brit. J. Haematol., 94, 99-104 (1996).
17. SCUDERI, R., PALUCKA, K.A., POKROVSKAJA, K., BJÖRKHOLM, M., WIMAN, K.G. and PISA, P., Cyclin-E over-expression in relapsed adult acute lymphoblastic leukemias of B-cell lineage. Blood, 87, 3360-3367 (1996).
18. SERRANO, M., HANNON, G.J. and BEACH, D., A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/cdk4. Nature (Lond.), 366, 704-707 (1993).
19. SESHADRI, R., LEE, C.S.L., HUI, R., McCAUL, K., HORSFALL, D.J. and SUTHERLAND, R.L., Cyclin-D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin. Cancer Res., 2, 1177-1184 (1996).
20. 1 progression. Oncogene, 9, 2663-2674 (1994).
21. VOLM, M., MATTERN, J., STAMMLER, G., ROYER-POKORA, B., SCHNEIDER, S., WEIRICH, A. and LUDWIG, R., Expression of resistance-related proteins in nephroblastoma after chemotherapy. Int. J. Cancer, 63, 193-197 (1995).
22. VOLM, M., STAMMLER, G., KOOMÄGI, R. and MATTERN, J., Co-expression of cyclin D1 and retinoblastoma gene product (pRb) in human squamous-cell lung carcinomas is associated with increased tumor take rate in nude mice. Int. J. Oncol., 9, 1253-1257 (1996).
23. ZINTL, F. and 15 OTHERS, Results with randomized BFM adopted studies for ALL therapy in childhood in East German counties. In: T. Büchner, G. Schellong, J. Hiddemann, J. Urbanitz and J. Ritter (eds.), Acute leukemias IV: prognostic factors, pp. 179-186, Springer, Berlin (1993).